Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis

Archives of Ophthalmology

Volumn 129, Issue 3, 2011, Pages 288-294

  Onal, Sumru ^a   Kazokoglu, Haluk ^a   Koc, Aylin ^a   Akman, Mehmet ^a   Bavbek, Tayfun ^a   Direskeneli, Haner ^a   Yavuz, Sule ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTIHISTAMINIC AGENT; CORTICOSTEROID; METHYLPREDNISOLONE; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ALOPECIA; ARTICLE; BEHCET DISEASE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEPRESSION; DERMATITIS; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MALE; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SIDE EFFECT; SURVIVAL; TREATMENT DURATION;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; BEHCET SYNDROME; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 79952608577     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.3     Document Type: Article

References (17)

1. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-380. (Pubitemid 39208563)
2. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol. 2006;34(4):365-374. (Pubitemid 44137557)
3. Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423-431. (Pubitemid 36399030)
4. Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320-335. (Pubitemid 38496041)
5. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692-1695. (Pubitemid 44830831)
6. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm. 2000;8(4):293-301. (Pubitemid 32174750)
7. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J. 2002;4(11)(suppl):928-930. (Pubitemid 35291273)
8. Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of lowdose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146(6):837.e1-844.e1. doi:10.1016/j.ajo.2008.08.038.
9. Plskova J, Greiner K, Forrester JV. Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144(1):55-61.
10. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335-339. (Pubitemid 46586530)
11. Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005;89(10):1254-1257. (Pubitemid 41638860)
12. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335(8697):1078-1080.
13. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516. (Pubitemid 41224845)
14. Harper SL, Chorich LJ, Foster CS. Principles of diagnosis and therapy. In: Foster CS, Vitale AT, eds. Diagnosis and Treatment of Uveitis. Philadelphia, PA: WB Saunders Co; 2002:79-103.
15. Onal S, Kazokoglu H, Direskeneli H, Yavuz S. Low-dose interferon alfa-2a therapy in severe uveitis associated with Behçet disease [letter]. Am J Ophthalmol. 2009;147(6):1109-1110.
16. Onal S, Kazokoglu H, Koc A, et al. Low dose and dose escalating therapy of interferon alfa-2a in the treatment of refractory and sight-threatening Behçet's uveitis. Clin Exp Rheumatol. 2009;27(2)(suppl 53):S113-S114.
17. Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol. 1994;21(6):1098-1100. (Pubitemid 24182284)